Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

HTLV-1 Extracellular Vesicles Promote Cell-to-Cell Contact.

Pinto DO, DeMarino C, Pleet ML, Cowen M, Branscome H, Al Sharif S, Jones J, Dutartre H, Lepene B, Liotta LA, Mahieux R, Kashanchi F.

Front Microbiol. 2019 Sep 18;10:2147. doi: 10.3389/fmicb.2019.02147. eCollection 2019.

2.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8. doi: 10.1016/j.chom.2018.12.001. Erratum in: Cell Host Microbe. 2019 Aug 14;26(2):296.

3.

Viral antigens detectable in CSF exosomes from patients with retrovirus associated neurologic disease: functional role of exosomes.

Anderson MR, Pleet ML, Enose-Akahata Y, Erickson J, Monaco MC, Akpamagbo Y, Velluci A, Tanaka Y, Azodi S, Lepene B, Jones J, Kashanchi F, Jacobson S.

Clin Transl Med. 2018 Aug 27;7(1):24. doi: 10.1186/s40169-018-0204-7.

4.

Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses.

Prévost J, Richard J, Medjahed H, Alexander A, Jones J, Kappes JC, Ochsenbauer C, Finzi A.

J Virol. 2018 Jun 13;92(13). pii: e00484-18. doi: 10.1128/JVI.00484-18. Print 2018 Jul 1.

5.

Ross River virus envelope glycans contribute to disease through activation of the host complement system.

Gunn BM, Jones JE, Shabman RS, Whitmore AC, Sarkar S, Blevins LK, Morrison TE, Heise MT.

Virology. 2018 Feb;515:250-260. doi: 10.1016/j.virol.2017.12.022. Epub 2018 Jan 8.

6.

Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology.

Jones JE, Long KM, Whitmore AC, Sanders W, Thurlow LR, Brown JA, Morrison CR, Vincent H, Peck KM, Browning C, Moorman N, Lim JK, Heise MT.

MBio. 2017 Nov 14;8(6). pii: e01456-17. doi: 10.1128/mBio.01456-17.

7.

Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein.

Bardhi A, Wu Y, Chen W, Li W, Zhu Z, Zheng JH, Wong H, Jeng E, Jones J, Ochsenbauer C, Kappes JC, Dimitrov DS, Ying T, Goldstein H.

J Virol. 2017 Sep 27;91(20). pii: e00937-17. doi: 10.1128/JVI.00937-17. Print 2017 Oct 15.

8.

Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells.

Cavrois M, Banerjee T, Mukherjee G, Raman N, Hussien R, Rodriguez BA, Vasquez J, Spitzer MH, Lazarus NH, Jones JJ, Ochsenbauer C, McCune JM, Butcher EC, Arvin AM, Sen N, Greene WC, Roan NR.

Cell Rep. 2017 Jul 25;20(4):984-998. doi: 10.1016/j.celrep.2017.06.087.

9.

Flow virometric sorting and analysis of HIV quasispecies from plasma.

Musich T, Jones JC, Keele BF, Jenkins LMM, Demberg T, Uldrick TS, Yarchoan R, Robert-Guroff M.

JCI Insight. 2017 Feb 23;2(4):e90626. doi: 10.1172/jci.insight.90626.

10.

Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function.

Alberti MO, Jones JJ, Miglietta R, Ding H, Bakshi RK, Edmonds TG, Kappes JC, Ochsenbauer C.

AIDS Res Hum Retroviruses. 2015 Dec;31(12):1278-96. doi: 10.1089/aid.2015.0074. Epub 2015 Jun 23.

11.

Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation.

Duverger A, Wolschendorf F, Anderson JC, Wagner F, Bosque A, Shishido T, Jones J, Planelles V, Willey C, Cron RQ, Kutsch O.

J Virol. 2014 Jan;88(1):364-76. doi: 10.1128/JVI.02682-13. Epub 2013 Oct 23.

12.

An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection.

Duverger A, Wolschendorf F, Zhang M, Wagner F, Hatcher B, Jones J, Cron RQ, van der Sluis RM, Jeeninga RE, Berkhout B, Kutsch O.

J Virol. 2013 Feb;87(4):2264-77. doi: 10.1128/JVI.01594-12. Epub 2012 Dec 12.

13.

Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation.

Shishido T, Wolschendorf F, Duverger A, Wagner F, Kappes J, Jones J, Kutsch O.

J Virol. 2012 Sep;86(17):9055-69. doi: 10.1128/JVI.00793-12. Epub 2012 Jun 13.

14.

Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O.

J Virol. 2012 Apr;86(8):4548-58. doi: 10.1128/JVI.06726-11. Epub 2012 Feb 15.

15.

Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity.

Lee HH, Meyer EH, Goya S, Pichavant M, Kim HY, Bu X, Umetsu SE, Jones JC, Savage PB, Iwakura Y, Casasnovas JM, Kaplan G, Freeman GJ, DeKruyff RH, Umetsu DT.

J Immunol. 2010 Nov 1;185(9):5225-35. doi: 10.4049/jimmunol.1001116. Epub 2010 Oct 1.

16.

Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.

Wolschendorf F, Duverger A, Jones J, Wagner FH, Huff J, Benjamin WH, Saag MS, Niederweis M, Kutsch O.

J Virol. 2010 Sep;84(17):8712-20. doi: 10.1128/JVI.00523-10. Epub 2010 Jun 10.

17.

Determinants of the establishment of human immunodeficiency virus type 1 latency.

Duverger A, Jones J, May J, Bibollet-Ruche F, Wagner FA, Cron RQ, Kutsch O.

J Virol. 2009 Apr;83(7):3078-93. doi: 10.1128/JVI.02058-08. Epub 2009 Jan 14.

18.

Blood exposure risk during procedural dermatology.

Holzmann RD, Liang M, Nadiminti H, McCarthy J, Gharia M, Jones J, Neel V, Schanbacher CF.

J Am Acad Dermatol. 2008 May;58(5):817-25. doi: 10.1016/j.jaad.2008.01.010.

PMID:
18423259
19.

High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds.

Jones J, Rodgers J, Heil M, May J, White L, Maddry JA, Fletcher TM 3rd, Shaw GM, Hartman JL 4th, Kutsch O.

Assay Drug Dev Technol. 2007 Apr;5(2):181-89.

PMID:
17477827
20.

A high-throughput drug screening system for HIV-1 transcription inhibitors.

Kempf MC, Jones J, Heil ML, Kutsch O.

J Biomol Screen. 2006 Oct;11(7):807-15. Epub 2006 Jul 10.

PMID:
16831859

Supplemental Content

Loading ...
Support Center